Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-165 ophthalmic gel in healthy volunteers
NCT03697876Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- Aug 2018
- Primary completion
- Jun 2024
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRO-165 in dry eye syndrome (DED) (2 arms), sponsored by Laboratorios Sophia. Primary endpoints: Adverse Events at 13 days and Ocular Comfort Index at 11 days. Started Aug 2018; status: completed.
02
Drugs
PRO-165
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03697876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697876.